Biocompatibility: Complement as mediator of tissue damage and as indicator of incompatibility

Experimental and Clinical Immunogenetics

Volumn 14, Issue 1, 1997, Pages 24-29

  Mollnes, Tom Eirik ^a,b  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Biocompatibility; Cardiopulmonary bypass; Complement; Heparin; Monoclonal antibodies; Neoepitope; Terminal complement complex

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3B RECEPTOR; HEPARIN; MONOCLONAL ANTIBODY;

BIOCOMPATIBILITY; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; CONFERENCE PAPER; ENDOTHELIUM CELL; GRAFT REJECTION; HOST RESISTANCE; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; TISSUE INJURY; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOCOMPATIBLE MATERIALS; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIUM, VASCULAR; HEPARIN; HUMANS; MATERIALS TESTING;

EID: 0030892285     PISSN: 02549670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Williams DF: Definitions in Biomaterials. Amsterdam, Elsevier, 1987.
2. Atkinson JP, Farries T: Separation of self from non-self in the complement system. Immunol Today 1987; 8:212-215.
3. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW: Complement activation during cardiopulmonary bypass: Evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304:497-503.
4. Gillinov AM, Devaleria PA, Winkelstein JA, Wilson I, Curtis WE, Shaw D, Yeh CG, Rudolph AR, Baumgartner WA, Herskowitz A, Cameron DE: Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thorac Surg 1993;55: 619-624.
5. Rinder CS, Rinder HM, Smith BR, Fitch JCK, Smith MJ, Tracey JB, Matis LA, Squinto SP, Rollins SA: Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995;96: 1564-1572.
6. Mollnes TE, Harboe M: Neoepitope expression during complement activation - A model for detecting antigenic changes in proteins and activation of cascades. Immunologist 1993;1:43-49.
7. Mollnes TE, Riesenfeld J, Garred P, Nordström E, Høgasen K, Fosse E, Gotze O, Harboe M: A new model for evaluation of biocompatibility: Combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif Organs 1995;19: 909-917.
8. Fosse E, Mollnes TE, Ingvaldsen B: Complement activation during major surgery with or without cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987;93:860-866.
9. Mollnes TE: Early- and late-phase activation of complement evaluated by plasma levels of C3d.g and the terminal complement complex. Complement 1985;2:156-164.
10. Videm V, Fosse E, Mollnes TE, Garred P, Svennevig JL: Time for new concepts about measurement of complement activation by cardiopulmonary bypass. Ann Thorac Surg 1992;54:725-731.
11. Deppisch R, Schmitt V, Bommer J, Mansch GM, Ritz E, Rauterberg EW: Fluid phase generation of terminal complement complex as a novel index of bioincompatibihty. Kidney Int 1990;37:696-706.
12. Videm V, Svennevlg JL, Fosse E, Semb G, Østerud A, Mollnes TE, Nielsen H: Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992;103:806-813.
13. Videm V, Mollnes TE, Garred P, Svennevig JL: Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 1991; 101:654-660.
14. Garred P, Mollnes TE: Immobilized heparin inhibits the increase in leukocyte surface expression of CD11b (CR3) and CD45 (LCA) induced by artificial surfaces. Artif Organs, in press.
15. Moen O, Høgasen K, Fosse E, Dregelid E, Brockmeier V, Venge P, Harboe M, Mollnes TE: Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg, in press.
16. Øvrum E, Mollnes TE, Fosse E, Holen EA, Tange G, Ringdal MAL, Videm V: High and low heparin dose with heparin-coated cardiopulmonary bypass: Activation of complement and granulocytes. Ann Thorac Surg 1995;60:1755-1761.
17. Nilsson-Ekdahl K, Nilsson B, Pekna M, Nilsson UR: Generation of iC3 at the interface between blood and gas. Scand J Immunol 1992;35:85-91.
18. Gong J, Larsson R, Ekdahl KN, Mollnes TE, Nilsson U, Nilsson B: Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol 1996;16:222-229.
19. Haviland DL, McCoy RL, Whitehead WT, Akama H, Molmenti EP, Brown A, Haviland JC, Parks WC, Perlmutter DH, Wetsel RA: Cellular expression of the C5a anaphylatoxin receptor (CSaR): Demonstration of CSaR on nonmyeloid cells of the liver and lung. J Immunol 1995; 154: 1861-1869.
20. Morgan BP: Complement membrane attack on nucleated cells: Resistance, recovery and non-lethal effects. Biochem J 1989;264:1-14.
21. Ishikawa S, Tsukada H, Bhattacharya J: Soluble complex of complement increases hydraulic conductivity in single microvessels of rat lung. J Clin Invest 1993;91:103-109.
22. Kroshus TJ, Rollins SA, Dalmasso AP, Elliott EA, Matis LA, Squinto SP, Bolman RM: Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995;60:1194-1202.
23. Fiane AE, Videm V, Scholz T, Pedersen T, Karlsen H, Geiran O, Foerster A, Mollnes TE, Aasen AO, Svennevig J: Ex vivo model for xenotransplantation. Transplant Proc 1995;27:3560-3561.
24. Mollnes TE, Videm V, Gotze O, Harboe M, Oppermann M: Formation of C5a during cardiopulmonary bypass - Inhibition by precoating with heparin. Ann Thorac Surg 1991;52:92-97.
25. Hetland G, Moen O, Bergh K, Høgåsen K, Hack CE, Mollnes TE, Fosse E: Quantification of both plasma- and leukocyte-associated C5a are essential for assessment of C5a generation in vivo. Ann Thorac Surg, in press.
26. Vogt W: Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes. Immunobiology 1996; 195:334-346.